In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: NeoGenomics appears undervalued with a 17.8% implied upside and high confidence in valuation, despite negative DCF outcomes contrasting strong Price/Sales and EV/Revenue metrics. Financial health shows strong liquidity and leverage but zero profitability and efficiency, indicating operational challenges. Monte Carlo analysis reveals minimal downside risk, highlighting limited near-term price decay potential.